Innovative Approach + Enabling MediPrint™
Technology = Successful Products
By using FDA cleared contact lenses, leveraging existing contact lens high speed manufacturing and adding the MediPrint™ process, the result is medicated contact lenses with sustained drug delivery and comfort.
Using an FDA cleared drug and FDA cleared contact lens leads to a shorter regulatory course via a 505 (b) (2) pathway.
We believe that initially mild to moderate glaucoma and ocular hypertension sufferers, likely from 45 – 70 years old, will benefit the most from our MediPrint™ contact lenses.
Key eye care stakeholders will benefit from an ongoing paradigm shift in eye care in the U.S. Optometrists are generally viewed as gatekeepers responsible for primary eye care, they are often the first to diagnose glaucoma, so they customarily see mild to moderate glaucoma patients, and they routinely fit contact lenses. Ophthalmologists typically see patients with more severe glaucoma, so their focus is on surgical and laser procedures, and treating less mild to moderate patients optimizes their patient flow.